389650
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
Market Cap & Net Worth: 389650 (389650)
389650 (KQ:389650) has a market capitalization of $391.86 Million (₩573.76 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13969 globally and #384 in its home market, demonstrating a 0.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 389650's stock price ₩70600.00 by its total outstanding shares 8126936 (8.13 Million).
389650 Market Cap History: 2024 to 2026
389650's market capitalization history from 2024 to 2026. Data shows growth from $227.57 Million to $391.86 Million (100.19% CAGR).
389650 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 389650's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
389650's market cap is 0.02 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.08x
389650's market cap is 0.08 times its annual earnings
0.11x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $227.57 Million | $9.54 Billion | $2.86 Billion | 0.02x | 0.08x |
Competitor Companies of 389650 by Market Capitalization
Companies near 389650 in the global market cap rankings as of March 18, 2026.
Key companies related to 389650 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
389650 Historical Marketcap From 2024 to 2026
Between 2024 and today, 389650's market cap moved from $227.57 Million to $ 391.86 Million, with a yearly change of 100.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩391.86 Million | -21.03% |
| 2025 | ₩496.21 Million | +118.05% |
| 2024 | ₩227.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 389650 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.86 Million USD |
| MoneyControl | $391.86 Million USD |
| MarketWatch | $391.86 Million USD |
| marketcap.company | $391.86 Million USD |
| Reuters | $391.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.